ENDOMETRIAL SEROUS ADENOCARCINOMA
Clinical trials for ENDOMETRIAL SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat uterine cancer: trial tests multiple drug combos
Disease control OngoingThis study is testing several drug combinations to see which works best for women with advanced endometrial cancer that has returned or stopped responding to treatment. It compares single drugs against combinations to see which can better control the cancer and keep it from growi…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists test Two-Drug attack on tough brain and solid tumors
Disease control OngoingThis early-stage study is testing the safety and best dose of a new oral drug, MLN0128, when given with the existing cancer drug bevacizumab. It is for adults with recurrent glioblastoma (a type of brain tumor) or other advanced solid tumors that have stopped responding to standa…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Major trial tests new weapon against advanced uterine cancer
Disease control OngoingThis large, late-stage study is testing whether adding an immunotherapy drug called pembrolizumab to standard chemotherapy works better for treating advanced or recurrent endometrial cancer. It involves over 800 patients with stage III, IV, or returning cancer. The goal is to see…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Three-Way drug fight against advanced uterine cancer
Disease control OngoingThis study aims to find the most effective drug combination for controlling advanced or recurrent endometrial cancer. It enrolled 349 patients to test three different mixes of chemotherapy and targeted therapy drugs. The goal is to see which combination best slows cancer growth a…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New scans and dye aim to spot hidden cancer spread
Diagnosis OngoingThis study is testing if two methods—a combined PET/CT scan and a special dye used during surgery—can better find cancer that has spread to lymph nodes in patients with high-risk endometrial cancer. The goal is to see if these methods are as good as or better than the standard su…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Mar 30, 2026 14:35 UTC
-
Scientists test Drug's direct impact on aggressive uterine cancer
Knowledge-focused OngoingThis early study aims to understand how a drug called triapine affects a specific type of aggressive uterine cancer. Researchers will give a single dose of the drug to 12 patients just before their scheduled cancer-removal surgery. They will then compare tumor tissue samples take…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:24 UTC